Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.

Yamanaka T, Sohn J, Sudo K, Mukai H, Yamamoto N, Chung CF, Lu YS, Lee KH, Lee SC, Iwasa T, Iwata H, Watanabe K, Jung KH, Tanabe Y, Kang SY, Yasojima H, Aogi K, Tokunaga E, Sim SH, Yap YS, Matsumoto K, Tseng LM, Umeyama Y, Noguchi E, Hata T, Kuchiba A, Shibata T, Nakamura K, Fujiwara Y, Tamura K, Yonemori K

Open source

DOI: 10.1007/s12282-026-01865-0
Published: 2026 Sep
Container: Breast cancer (Tokyo, Japan)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12282-026-01865-0,
  title = {Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.},
  author = {Yamanaka T and Sohn J and Sudo K and Mukai H and Yamamoto N and Chung CF and Lu YS and Lee KH and Lee SC and Iwasa T and Iwata H and Watanabe K and Jung KH and Tanabe Y and Kang SY and Yasojima H and Aogi K and Tokunaga E and Sim SH and Yap YS and Matsumoto K and Tseng LM and Umeyama Y and Noguchi E and Hata T and Kuchiba A and Shibata T and Nakamura K and Fujiwara Y and Tamura K and Yonemori K},
  year = {2026},
  journal = {Breast cancer (Tokyo, Japan)},
  doi = {10.1007/s12282-026-01865-0},
  url = {https://doi.org/10.1007/s12282-026-01865-0}
}

RIS

TY  - JOUR
TI  - Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.
AU  - Yamanaka T
AU  - Sohn J
AU  - Sudo K
AU  - Mukai H
AU  - Yamamoto N
AU  - Chung CF
AU  - Lu YS
AU  - Lee KH
AU  - Lee SC
AU  - Iwasa T
AU  - Iwata H
AU  - Watanabe K
AU  - Jung KH
AU  - Tanabe Y
AU  - Kang SY
AU  - Yasojima H
AU  - Aogi K
AU  - Tokunaga E
AU  - Sim SH
AU  - Yap YS
AU  - Matsumoto K
AU  - Tseng LM
AU  - Umeyama Y
AU  - Noguchi E
AU  - Hata T
AU  - Kuchiba A
AU  - Shibata T
AU  - Nakamura K
AU  - Fujiwara Y
AU  - Tamura K
AU  - Yonemori K
PY  - 2026
JO  - Breast cancer (Tokyo, Japan)
DO  - 10.1007/s12282-026-01865-0
UR  - https://doi.org/10.1007/s12282-026-01865-0
ER  -

APA

T, Y., J, S., K, S., H, M., N, Y., CF, C., YS, L., KH, L., SC, L., T, I., H, I., K, W., KH, J., Y, T., SY, K., H, Y., K, A., E, T., SH, S., YS, Y., K, M., LM, T., Y, U., E, N., T, H., A, K., T, S., K, N., Y, F., K, T., & K, Y. (2026). Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.. Breast cancer (Tokyo, Japan). https://doi.org/10.1007/s12282-026-01865-0

Source records

pubmed · retrieved 2026-09-25T07:41:17.797Z
europe-pmc · retrieved 2026-09-25T07:41:17.795Z